Clinical

Persistent high-level EBNA-1 peptide antibody titers could be used to identify multiple sclerosis (MS) vs neuromyelitis optica spectrum disorder (NMOSD).

The efficacy and safety of efgartigimod in pediatric patients will need to be further validated with future studies.

Meta-analysis across B-cell lymphomas shows zanubrutinib (Brukinsa) delivers higher ORR/CR than acalabrutinib (Calquence) or ibrutinib among BTK inhibitors.

Federal RHTP funding often misses states with the highest rural mortality and greatest projected Medicaid funding losses, researchers found.

Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd Schlesinger, MD.

A deeper understanding of vitiligo's autoimmune mechanisms has fundamentally transformed vitiligo care, explains Susan Taylor, MD.

Phase 3 trials show deucravacitinib, the first TYK2 inhibitor approved for adults with active psoriatic arthritis (PsA), improves both joint and skin symptoms.

April Armstrong, MD, MPH, discusses choosing AD therapies, JAK inhibitor safety, response measures, and emerging treatments shaping the field.

Domain Adaptation leverages lymphoma EHRs to better predict infection risk from treatment-related immune suppression in CLL, boosting Matthews correlation coefficient.

The FDA approved kinase inhibitors, biologics, a pancreatic cancer device, GLP-1 updates, and a new ultrarare disease pathway in February 2026.

The politicization of public health is eroding vaccine confidence, risking lower uptake and potential disease outbreaks, says Noel T. Brewer, PhD.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

Immunotherapies are transforming treatment and improving outcomes for patients with advanced cSCC, according to Todd Schlesinger, MD.

The rise in CRC in adults younger than 65 underscores the need for early screening and prevention efforts.

The approval is expected to offer more affordable treatment options and potentially reduce asthma-related complications nationwide.

Bidisha Mandal, PhD, concluded her conversation with AJMC by emphasizing the need for policy support and further research to maximize telehealth's impact.

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy.

Experts weigh neoadjuvant vs adjuvant immunotherapy in resectable lung cancer, balancing PD‑L1, pCR, surgery timing, and toxicity.

These new data highlight CRC screening gaps, as well as disparities in incidence and survival.

Phase 3 data show povorcitinib delivers rapid lesion clearance in HS, improves quality of life outcomes, and offers favorable safety through 24 weeks.

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor.

Food-insecure adults have fewer annual health visits but rely more on telehealth for primary care, lowering per-visit costs, says Bidisha Mandal, PhD.

Patients with myasthenia gravis had a more consistent clinical response and fewer deteriorations when using add-on therapy early.

Investigators in China touted durable responses seen in a phase 2 study of the CAR T-cell therapy relma-cel, which has a similar mechanism of action as liso-cel. At present, there are no approved CAR T-cell therapies for relapsed/refractory mantle cell lymphoma in China.

A new review highlights the potential to develop ways to better anticipate and treat Richter transformation in patients with chronic lymphocytic leukemia.